Effect of cheese containing Lactobacillus delbrueckii subsp. Lactis CRL 581 on blood pressure in prehypertensive and stage 1 hypertensive subjects

ABSTRACT Hypertension is one of the main risk factors for cardiovascular disease. Functional foods containing bioactive peptides have been proposed as a strategy to decrease blood pressure (BP) in subjects under no pharmacological treatment. The aim of this study was to compare the effect of low-sod...

Full description

Saved in:
Bibliographic Details
Published inRevista chilena de nutrición Vol. 46; no. 6; pp. 701 - 707
Main Authors Salazar, Martín, Malpeli, Agustina, Hebert, Elvira, Cravero, Ricardo, Espeche, Walter, Sisnieguez, Cecilia Leiva, Stavile, Rodolfo N., March, Carlos, Sisnieguez, Carlos Leiva, Tavella, Marina, Disalvo, Liliana, Fasano, Victoria, Magrini, Graciano, Visentin, Dimas, Taranto, M. Pía, González, Horacio F.
Format Journal Article
LanguageEnglish
Published Sociedad Chilena de Nutrición, Bromatología y Toxicología 01.12.2019
Subjects
NUTRITION & DIETETICS
Lactobacillusdelbrueckii
Queso
Prehipertensión
Functional foods
Biopéptidos
Biopeptides
Alimentos funcionales
Cheese
Lactobacillus delbrueckii
Pre-hypertension
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT Hypertension is one of the main risk factors for cardiovascular disease. Functional foods containing bioactive peptides have been proposed as a strategy to decrease blood pressure (BP) in subjects under no pharmacological treatment. The aim of this study was to compare the effect of low-sodium, low-fat (LSLF) cheese and LSLF cheese containing Lactobacillus delbrueckii subsp. lactis CRL 581 (LSLF581) on BP in pre-hypertensive and stage 1 hypertensive subjects. Sixty-one pre-hypertensive and stage 1 hypertensive subjects assigned to one of twos (LSLF, n= 29 and LSLF581, n= 32) participated in this 12-month prospective, randomized, double-blind, crossover trial. Twenty-four h ambulatory BP monitoring was performed at the beginning and at the end of each four-week study period. Systolic and diastolic BP decreased in both study groups, but differences between groups were not significant (systolic, −1.78 and −0.2 mmHg; diastolic, −1.54 and −0.42 mmHg in LSLF581 and LSLF, respectively). Although our results could not support a BP lowering effect of LSLF581, small BP reductions could favorably prevent cardiovascular disease development.
ISSN:0717-7518
0717-7518
DOI:10.4067/S0717-75182019000600701